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Abstract
Rationale: Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future
clinical trials, but even if they prove effective, high drug costs may limit their economic viability.
Objectives: To inform clinical trial design by estimating the potential costs and effectiveness of rifapentine-based regimens
for treatment of latent tuberculosis infection (LTBI).
Methods: We used a Markov model to estimate cost and societal benefits for three regimens for treating LTBI: Isoniazid/
rifapentine daily for one month, isoniazid/rifapentine weekly for three months (self-administered and directly-observed),
and isoniazid daily for nine months; a strategy of ‘‘no treatment’’ used for comparison. Costs, quality-adjusted life-years
gained, and instances of active tuberculosis averted were calculated for all arms.
Results: Both daily isoniazid/rifapentine for one month and weekly isoniazid/rifapentine for three months were less
expensive and more effective than other strategies under a wide variety of clinically plausibly parameter estimates. Daily
isoniazid/rifapentine for one month was the least expensive and most effective regimen.
Conclusions: Daily isoniazid/rifapentine for one month and weekly isoniazid/rifapentine for three months should be studied
in a large-scale clinical trial for efficacy. Because both regimens performed well even if their efficacy is somewhat reduced,
study designers should consider relaxing non-inferiority boundaries.
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Introduction
Treatment of latent tuberculosis infection (LTBI) with isoniazid
has long been established as an effective means to prevent the
development of active tuberculosis [1,2,3] and is currently the
standard of care in the United States and other high income
countries [4,5]. While such treatment clearly prevents TB-related
morbidity and mortality, from a purely economic standpoint
treating a case of LBTI is also less expensive than treating a case of
active TB [6,7,8] and is therefore both economically and clinically
desirable. Even accounting for the necessity of treating multiple
individuals with LTBI to prevent one instance of active TB,
currently-recommended regimens are expected to be cost-saving
compared to a strategy of no treatment [6].
Despite its proven benefit, the overall utility of isoniazid
monotherapy has been limited, as nearly half of patients started
on isoniazid fail to complete a full course.[9,10] Shorter regimens
lead to improved completion rates [10,11] but are not always cost-
effective [7]. Therefore, it would be prudent to demonstrate the
economic viability of any proposed regimen prior to testing it in a
large-scale clinical trial.
Recently, new interest has focused on regimens containing
rifamycins, particularly rifapentine, for LTBI treatment [12,13]. A
recently-completed large-scale clinical trial of isoniazid plus
rifapentine given weekly for three months (the PREVENT TB
study)found the efficacyof this shorter regimen tobe non-inferior to
isoniazid monotherapy but with much better completion rates [14].
However, inthisstudy directly-observed therapy (DOT) was used to
improve adherence, greatly increasing the regimen’s cost. Another
option, self-administered isoniazid plus rifapentine given daily for
one month, has been proven efficacious in the murine model [15]
and is currently being considered for study in patients with human
immunodeficiency virus infection. Because this regimen is not
intermittent, it could be given without DOT (current guidelines
recommend DOT for all intermittent regimens [4]) and would be
even shorter, perhaps increasing completion rates even further.
Of course, these advantages are currently only theoretical, and
they come with a price. Daily rifapentine is relatively expensive, so
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offset this higher cost. Post hoc cost-effectiveness analysis has
traditionally been utilized for answering questions related to the
economic viability of new interventions or strategies, but in an effort
to increase the efficiency of clinical trial design, we propose a ‘‘pre
hoc’’ cost-effectiveness analysis of two rifapentine-containing regi-
mens to determine thresholds of key parameters that would
determine the regimens’ economic viability. Consideration of these
thresholds can help study planners determine which treatment
options have the greatest potential of economic viability and
therefore should be of highest priority.
Methods
We modified a previously-described Markov model created with
TreeAge Pro 2009 (release 1.0.2; TreeAge Software, Inc.,
Williamstown, MA) to compare the costs, effectiveness, and cost-
effectiveness of four different regimens for treating a cohort of
individuals recently infected with TB:
1. Isoniazid 300 mg daily for 9 months, self-administered (9H-
SAT daily, 270 doses)
2. Isoniazid 900 mg plus rifapentine 900 mg once-weekly for 3
months, self-administered (3HP-SAT weekly, 12 doses)
3. Isoniazid 900 mg plus rifapentine 900 mg once-weekly for 3
months, by directly-observed therapy (3HP-DOT weekly, 12
doses)
4. Isoniazid 300 mg plus rifapentine 600 mg daily for 1 month,
self-administered (1HP-SAT daily, 30 doses).
Full details of the model (including schematic) are described
elsewhere [6] but briefly, all individuals in the hypothetical cohort
were assumed to start ‘‘on treatment.’’ Patients were moved to ‘‘off
Table 1. Base-case parameters and probabilities used in the model.
Variable Base-Case Estimate Range Reference
Lifetime probability of TB activation 0.06 0.06–0.4 [4,17,18,19]
TB risk reduction from 9H-SAT daily:
0–2 months 0 [16]
3–5 months 0.21 0.14–0.21 [16]
6–8 months 0.69 0.44–0.69 [16]
9 months 0.93 0.60–0.93 [16]
TB risk reduction from 3HP weekly (SAT or DOT):
0–1 months 0 (assumed)
2 months 0.47 (interpolated)
3 months 0.93 0.60–0.93 [14]
TB risk reduction from 1HP-SAT daily:
0 months 0 (assumed)
1 months 0.93 0.6–0.93 (assumed)
Probability of non-adherence (other than toxicity):
9H-SAT daily 0.47 0–1 [9,20]
3HP-DOT weekly 0.10 0–1 [14]
3HP-SAT weekly 0.13 0–1 [16], assumed
1HP-SAT weekly 0.05 0–1 (assumed)
Probability of severe toxicity (treatment stops):
9H-SAT daily 0.014 0.001–0.2 [9,14,16]
3HP weekly (SAT or DOT) 0.05 0.006–0.03 [14]
1HP-SAT daily 0.02 0.005–0.10 (assumed)
Probability of hospitalization after severe toxicity 0.015 0.01–0.02 [21]
Probability of death due to drug toxicity 0.003 0–0.01 [16,21]
Probability of extended treatment (active disease) 0.124 [22]
Probability of death from TB 0.04 0.03–0.05 [23]
Number of secondary cases per active case 1.2 0–1.2 [16,24]
9H=isoniazid daily for 9 months, 3HP=isoniazid plus rifapentine weekly for 3 months, 1HP=isoniazid plus rifapentine daily for 1 month. SAT=self-administered therapy,
DOT=directly-observed therapy.
doi:10.1371/journal.pone.0022276.t001
Table 2. Utility adjustments for events occurring in the
model, expressed as fractions of a life-year.
Event Adjustment Range Reference
LTBI treatment 0.97 0.95–0.97 [25]
Treatment-limiting toxicity 0.75 0.65–085 (assumed)
Hospitalization 0.50 0.40–0.60 (assumed)
Treatment of active TB 0.90 0.64–0.93 [25]
Prior TB 0.95 0.85–1 (assumed)
doi:10.1371/journal.pone.0022276.t002
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toxicity, or stopped due to non-adherence. All individuals were at
risk of developing active TB, although that risk was decreased by
treatment witheach of the regimens; partial protection was afforded
to patients who stopped treatment early in the 9H [16] or 3HP
(assumed) arms (see Table 1). Persons who developed active TB
were at risk of dying from TB during their treatment period, but
their risk of death reverted to age-specific mortality once treatment
was completed. We assumed that all individuals with active TB who
did not die were successfully treated and did not relapse.
Costs were updated to 2011 U.S. dollars, and efficacy, toxicity,
and adherence parameters for 3HP-DOT weekly were updated
based on the recently-completed clinical trial [14]. Base-case
parameter estimates are shown in Table 1, utility adjustments are
shown in Table 2, and base-case estimates for costs (U.S.) are
shown in Tables 3 and 4.
Sensitivityanalysesfocusedonparametersofthetwotrialregimens
(daily isoniazid/rifapentine for one month and weekly isoniazid/
rifapentine for 3 months) in an effort to determine threshold values
above/below which these combinations would no longer be
economically viable when compared to standard therapy (nine
months of isoniazid) or to each other. Ranges for parameter estimates
were taken from the available literature (U.S.) where available; where
no literaturewas available, ranges were assumed as an approximation
based on clinical judgment. Ranges for costs were determined by
adding and subtracting 25% to the base-case estimate.
The model was run with cycles of one month duration over the
life of each patient, and cohort analysis was used to calculate costs,
quality-adjusted life-years (QALYs), and number of active cases.
We followed recommendations from the Panel on Cost Effective-
ness in Health and Medicine as appropriate [31]. Because we were
interested in cost-saving regimens, a willingness-to-pay threshold
of $0 was selected; therefore, in our analysis only regimens that
were both more effective and less expensive than the standard of
care (‘‘dominant’’) were considered a good use of resources.
Results
The base-case costs, QALYs, and incremental cost-effectiveness
of the evaluated strategies are shown in Table 5 and Figure 1. All
drug regimens dominated the ‘‘no treatment’’ strategy. The other
regimens are summarized as follows:
1. 1HP-SAT daily dominated all other drug regimens
2. 3HP-SAT dominated 9H-SAT daily
3. 3HP-DOT weekly was more effective than 9H-SAT daily at a
cost of $1,415 per QALY.
Sensitivity analysis
Pairwise comparisons were made between trial regimens and
established regimens, and thresholds were calculated for key
parameters above/below which the trial regimens were no longer
cost-saving.
Adherence. If the adherence for 1HP-SAT daily is below
83% (base-case estimate=95%), that regimen no longer
dominates 3HP-SAT weekly; if its adherence is less than 71%, it
no longer dominates 9H-SAT daily. If the adherence for 3HP-
SAT weekly is below 70% (base-case estimate=87%), it no longer
dominates 9H-SAT daily, and below 67% it no longer dominates
3HP-DOT weekly.
Efficacy. Assuming base-case values for other parameters, the
efficacy of 1HP-SAT daily could be as low as 81% (base-case
estimate=87%) and it would still dominate all other regimens; its
efficacy could be as low as 70% and still dominate 9H-SAT daily.
Toxicity. If the rate of severe toxicity for 1HP-SAT daily is
above 7% (base-case estimate=2%), 3HP-SAT becomes the
preferred regimen, though 1HP-SAT daily continues to dominate
9H-SAT daily until its rate of severe toxicity exceeds 10%. There
Table 3. Costs in US$ associated with treating latent TB
infection.
Estimate Range Reference
9H-SAT daily cost per month:
Number of doses 30
Medications $1.20 [26]
Monthly visit* $26.52 [8]
DOT $0
Total $27.72 $20–34
3HP-DOT weekly cost per month $174.62 $131–218
Number of doses 4
Medications $53.68 [26]
Monthly visit* $26.52 [8]
DOT $96.30 [27,28]
Total $176.50 $133–221
3HP-SAT weekly cost per month:
Number of doses 4
Medications 53.68 [26]
Monthly visit* $26.52 [8]
DOT $0
Total $80.20 $60–100
1HP-SAT daily cost per month:
Number of doses 30
Medications $267.30 [26]




Lab monitoring (4 @$41.20) $164.80 $124–206 [8]
Hospitalization (7 days) $5,537.84 $4,153–$6,922 [29]
*Average cost of routine monitoring and evaluation for mild toxicity under the
assumption that 40% of individuals will require monthly monitoring of
transaminases and 1.4% will have toxicity that will require a physician visit but
not result in treatment discontinuation.
doi:10.1371/journal.pone.0022276.t003
Table 4. Costs in US$ associated with treating active TB.
Total cost Range Reference
Diagnosis $466.01 $350–583 [27]
Inpatient treatment $10,402.37 $7,802–13,003 [27]
Outpatient (months 1 & 2) $299.25 $224–374 [27]
Outpatient treatment (months 3+) $261.01 $196–326 [27]
Contact tracing/testing $488.65 $366–611 [28,30]
Total per case - 6 months $13,000
Total per case - 9 months $13,783
doi:10.1371/journal.pone.0022276.t004
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sensitivity analysis range (0.6%–3%).
A two-way sensitivity analysis was done to assess the tradeoff
between adherence and efficacy of 1HP-SAT daily and is shown in
Figure 2. Also, under the assumption that all regimens are equally
efficacious, a two-way sensitivity analysis was performed to show
the effect of various adherence adjustments to the trial regimens
1HP-SAT daily and 3HP-SAT weekly; the strategy graph is shown
in Figure 3.
Varying the model’s costs and utilities in one-way sensitivity
analyses over the range of estimates did not identify any thresholds
where the recommended therapy would change. Likewise, varying
the number of secondary cases per active case over the specified
range did not identify any thresholds.
Discussion
In our model, 1HP-SAT daily (isoniazid plus rifapentine self-
administered daily for one month) was cost-saving compared to
other options under a wide range of clinically plausible scenarios.
Moreover, assuming high rates of adherence to this regimen, even
if it was only 81% efficacious (compared to 93% for 9H-SAT daily)
it would still maintain its overall economic advantage. 3HP-SAT
weekly (Isoniazid plus rifapentine self-administered once-weekly
for three months) also performed well compared to established
regimens.
These results have important implications for proposed future
clinical trials. First, they suggest that trials of 1HP-SAT daily and
3HP-SAT weekly are warranted, as successful demonstration of
the efficacy of either proposed regimen would produce an option
for treating LTBI that would be cost-saving compared to
currently-available regimens. Second, the results indicate that
tight non-inferiority bounds for efficacy would not be necessary,
allowing for reduced sample size and a less expensive study.
A significant limitation of our study is that the point estimates
for several parameters related to the proposed regimens are
assumed. However, we chose these values merely as starting points
for our analysis; the primary goal of our trial was to determine
Table 5. Costs, effectiveness, and incremental cost-effectiveness ratios for the four drug regimens in order of increasing
effectiveness, referenced to the strategy of ‘‘no treatment.’’








Cases of active TB
per 1000 contacts
No treatment $1,589 (ref) 22.61149 (ref) (Dominated) 64
9H $724 2$865 22.64937 0.037884 (Dominated) 22
3HP-SAT $562 2$162 22.66685 0.017472 (Dominated) 15
3HP-DOT $754 $192 22.66836 0.001511 (Dominated) 13
1HP $392 2$362 22.67849 0.010128 10
doi:10.1371/journal.pone.0022276.t005
Figure 1. Cost-effectiveness plot of the four regimens and the ‘‘no treatment’’ strategy. Incremental cost-effectiveness ratios (ICER) are
represented by the inverse slope of the dotted and dashed lines between strategies. Abbreviations: 9H=isoniazid daily for 9 months, 3HP=isoniazid
plus rifapentine weekly for 3 months, 1HP=isoniazid plus rifapentine daily for 1 month. SAT=self-administered therapy, DOT=directly-observed therapy.
doi:10.1371/journal.pone.0022276.g001
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favorable or not favorable. Because our results suggest that the
proposed regimens are economically advantageous over a wide
range of estimates, we believe that any trial that would
demonstrate the efficacy of these regimens would likely show
adherence and toxicity values within the acceptable range shown
in our study.
Another limitation of our study is that it is based on U.S. data
and is therefore applicable only to similar settings. How these
regimens would perform in areas of the world with high rates of
reinfection is unknown. Also, we assumed the ability to accurately
exclude active TB among members of the cohort. In areas of the
world where diagnostic capability is somewhat limited, there may
be an increased risk of drug resistance (possibly rifamycin
resistance) among patients who develop active disease, which
could dramatically alter costs. Further studies of these regimens in
other areas of the world would be warranted.
We used drug costs from 2011 U.S. public health pricing. While
drug prices are fluid, they tend to trend down over time. Because
isoniazid is already very inexpensive, the primary driver of the cost
difference among regimens is rifapentine; if it becomes cheaper,
our results would only become more robust.
It is possible that TB reactivation rates in the contemporary era
within the United States are significantly less than the older
estimates (from 1975) used in our model [32]. However, even with
a reactivation rate of half of the base-case estimate (6% lifetime
risk), 1HP-SAT daily and 3HP-SAT weekly continued to
outperform other options (including the ‘‘no-treatment’’ strategy).
Likewise, with a relative risk of reactivation of 10 (corresponding to
rates seen in untreated HIV infection [18]), these two regimens
were still cost-saving compared to standard therapy. With
activation rates as low as 0.004/year (estimated for low-risk
reactors [32]), the ‘‘no treatment’’ regimen dominates other
regimens except 1HP-SAT daily, which would still be considered
cost-effective (incremental cost-effectiveness ratio $12,668) under
Figure 2. Two-way sensitivity analysis strategy graph comparing risk reduction and adherence for isoniazid/rifapentine daily for
one month (1HP). The clear area shows combinations of adherence and risk reduction for 1HP that are high enough that 1HP is a cost-saving
regimen. In the cross-hatched area, all combinations of adherence and risk reduction for 1HP are too low, so isoniazid/rifapentine monthly for 12
weeks self-administered (3HP-SAT) is preferred regimen.
doi:10.1371/journal.pone.0022276.g002
Figure 3. Two-way sensitivity analysis strategy graph compar-
ing adherence for isoniazid/rifapentine daily for one month
(1HP) vs. isoniazid/rifapentine weekly for three months self-
administered (3HP-SAT). In the diagonal cross-hatched area, 1HP is
cost-saving and therefore the preferred regimen. In the horizontal
cross-hatched area, 3HP-SAT is cost-saving. In the shaded area, neither
regimen is cost-saving when compared to isoniazid monotherapy daily
for nine months (9H), which is the preferred regimen.
doi:10.1371/journal.pone.0022276.g003
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U.S.
In summary, we have shown that treatment of LTBI with
isoniazid plus rifapentine given either daily for one month or
weekly for three months, all by self-administered therapy, has the
potential to be cost-saving compared to standard therapy with
isoniazid. We suggest that these two regimens should be studied in
a randomized, controlled trial.
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